Arana superhumanises CSL

By Dylan Bushell-Embling
Friday, 06 June, 2008

Arana (ASX: AAH) and CSL (ASX: CSL) have completed their second collaborative research project together, paving the way for CSL to develop new pharmaceuticals.

A lead antibody from the CSL pharmaceutical pipeline was run through Arana's Superhumanisation technology, which converts murine antibodies into a humanised form. It was further optimised for affinity using Arana's EvoGene technology platform.

As well as the one-off payment for completing the research, Arana will also be entitled to royalties if CSL choose to develop one of the modified antibodies for clinical testing.

This is the second time CSL and Arana have collaborated, and the third collaborative project Arana has completed.

Arana's stock price has remained relatively stable despite the announcement.

Related News

Quitting smoking increases life expectancy even for seniors

Although the benefits of quitting smoking diminish with age, there are still substantial gains...

Stem cell transplants treat blindness in mini pigs

Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...

Sugary drinks raise cardiovascular disease risk, but occasional sweets don't

Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd